An experimental tumor system has been developed in which: (a) the molecular nature and genetic origin of unique tumor-specific transplantation antigens have been characterized, (b) syngeneic tumor-specific monoclonal antibodies and T cell lines have been generated, (c) tumor variants and gene transfectants carrying various antigenic components have been isolated, (d) specific changes of the tumor-specific antigenicity clearly correlate with malignant behavior, and (e) a large number of control tumors is available. The well-characterized tumor model will be used to develop several new complementary approaches for immunological manipulation of cancer cells in tumor-bearing individuals. This long-term objective will be achieved by (a) stimulating clonotypes or classes of effector cells previously unrecruited, suppressed or reactive with different tumor antigens, (b) providing an appropriate strong """"""""second signal"""""""" or (c) improving antigen presentation. To elicit previously unrecruited T cells, one approach will be to immunize tumor cells whose level of MHC class I expression is either drastically increased by gamma interferon treatment, or decreased by selection of class I-deficient variants. In a second complementary approach, idiotypic and anti-idiotypic antibodies and/or cells will be used to stimulate complementary clones of tumor-specific effector T cells. To elicit a """"""""second signal"""""""" which helps an immune response to weak tumor-specific antigens without mutagenizing or derivatizing them, tumor cells will be transfected with allogeneic class I genes. Tumor cells will also be transfected with class II genes which may endow the tumor cells with certain antigen-presenting function and thus increase the immune response to the cancer cells. Of course, new tumor variants may escape the augmented immunity resulting from these immune manipulations, and the phenotypic alteration of these variants will indicate the relevant destruction mechanism operating. Once the above approaches have been made optimal using highly immunogenic tumors, the procedures will be adapted to more aggressive or even metastatic variants of the same tumor or poorly immunogenic spontaneous tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA022677-15
Application #
3481932
Study Section
Special Emphasis Panel (NSS)
Project Start
1978-02-01
Project End
1994-01-31
Budget Start
1992-02-01
Budget End
1993-01-31
Support Year
15
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
Schools of Medicine
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Binder, David C; Engels, Boris; Arina, Ainhoa et al. (2013) Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res 1:123-33
Loukinova, E; Dong, G; Enamorado-Ayalya, I et al. (2000) Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 19:3477-86
Pekarek, L A; Starr, B A; Toledano, A Y et al. (1995) Inhibition of tumor growth by elimination of granulocytes. J Exp Med 181:435-40
Monach, P A; Meredith, S C; Siegel, C T et al. (1995) A unique tumor antigen produced by a single amino acid substitution. Immunity 2:45-59
Seung, L P; Seung, S K; Schreiber, H (1995) Antigenic cancer cells that escape immune destruction are stimulated by host cells. Cancer Res 55:5094-100
Seung, L P; Rowley, D A; Dubey, P et al. (1995) Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci U S A 92:6254-8
Pekarek, L A; Weichselbaum, R R; Beckett, M A et al. (1993) Footprinting of individual tumors and their variants by constitutive cytokine expression patterns. Cancer Res 53:1978-81
Koeppen, H; Acena, M; Drolet, A et al. (1993) Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes. Eur J Immunol 23:2770-6
Seung, S; Urban, J L; Schreiber, H (1993) DNA sequence analysis of T-cell receptor genes reveals an oligoclonal T-cell response to a tumor with multiple target antigens. Cancer Res 53:840-5
Teng, M N; Turksen, K; Jacobs, C A et al. (1993) Prevention of runting and cachexia by a chimeric TNF receptor-Fc protein. Clin Immunol Immunopathol 69:215-22

Showing the most recent 10 out of 33 publications